A study of a treatment for chronic inflammatory demyelinating neuropathy (CIDP) suggests that 50% of the patients who responded to treatment with Gamunex (Immune Globulin Intravenous, 10% Caprylate/Chromatography Purified) required two treatments before they first exhibited improvements.
Data presented at the American Neurological Association meeting in Salt Lake City concluded that “further studies in CIDP are warranted to more clearly define the duration of treatment required to achieve and maintain maximal response to IVIG therapy.”
The study of CIDP – a neurological condition that damages peripheral nerves and causes progressive muscle weakness in the arms and legs – was funded by Talecris Biotherapeutics.
Study author Norman Latov, from Cornell University, said: “Our data suggest that some patients may require more than one treatment course to achieve clinical response and additional IGIV-C treatments might clinically benefit a substantial number of CIDP patients.”
The data reported at the association meeting is a sub-analysis of a larger phase III study published in the February 2008 issue of The Lancet Neurology.
Results of that study were used to support the recent approval of Gamunex by the US Food and Drug Administration as a treatment for CIDP.
Copyright PA Business 2008
“Delay with approval by insurance” – K. Haderlein, Los Angeles, USA